Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,093 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Incidence and Phenotype at Diagnosis of Very-early-onset Compared with Later-onset Paediatric Inflammatory Bowel Disease: A Population-based Study [1988-2011].
Bequet E, Sarter H, Fumery M, Vasseur F, Armengol-Debeir L, Pariente B, Ley D, Spyckerelle C, Coevoet H, Laberenne JE, Peyrin-Biroulet L, Savoye G, Turck D, Gower-Rousseau C; EPIMAD Group. Bequet E, et al. J Crohns Colitis. 2017 May 1;11(5):519-526. doi: 10.1093/ecco-jcc/jjw194. J Crohns Colitis. 2017. PMID: 28453757
Comparative Risk of Incident Cancer in Patients with Inflammatory Bowel Disease with Prior Non-digestive Malignancy According to Immunomodulator: a Multicentre Cohort Study.
Poullenot F, Amiot A, Nachury M, Viennot S, Altwegg R, Bouhnik Y, Abitbol V, Nancey S, Vuitton L, Peyrin-Biroulet L, Biron A, Fumery M, Picon L, Vidon M, Reenaers C, Serrero M, Savoye G, Beaugerie L, Rivière P, Laharie D. Poullenot F, et al. J Crohns Colitis. 2022 Nov 1;16(10):1523-1530. doi: 10.1093/ecco-jcc/jjac061. J Crohns Colitis. 2022. PMID: 35512337
How to Manage Inflammatory Bowel Disease Patients When They Withdraw Anti-Tumour Necrosis Factor [Anti-TNF] Due to Severe Anti-TNF-Induced Skin Lesions? A Multicentre Cohort Study.
Cottron C, Treton X, Altwegg R, Reenaers C, Amiot A, Fumery M, Vuitton L, Peyrin-Biroulet L, Bouguen G, Dewit O, Nancey S, Caillo L, Roblin X, Beylot-Barry M, Rivière P, Laharie D. Cottron C, et al. J Crohns Colitis. 2022 Aug 30;16(8):1202-1210. doi: 10.1093/ecco-jcc/jjac035. J Crohns Colitis. 2022. PMID: 35218189 Free article.
One-year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multicentre cohort study.
Amiot A, Serrero M, Peyrin-Biroulet L, Filippi J, Pariente B, Roblin X, Buisson A, Stefanescu C, Trang-Poisson C, Altwegg R, Marteau P, Vaysse T, Bourrier A, Nancey S, Laharie D, Allez M, Savoye G, Moreau J, Vuitton L, Viennot S, Aubourg A, Pelletier AL, Bouguen G, Abitbol V, Gagniere C, Bouhnik Y; OBSERV-IBD study group and the GETAID. Amiot A, et al. Aliment Pharmacol Ther. 2017 Aug;46(3):310-321. doi: 10.1111/apt.14167. Epub 2017 Jun 8. Aliment Pharmacol Ther. 2017. PMID: 28593685
Infliximab for refractory ulcerative proctitis.
Bouguen G, Roblin X, Bourreille A, Feier L, Filippi J, Nancey S, Bretagne JF, Flourié B, Hébuterne X, Bigard MA, Siproudhis L, Peyrin-Biroulet L. Bouguen G, et al. Aliment Pharmacol Ther. 2010 Jun;31(11):1178-85. doi: 10.1111/j.1365-2036.2010.04293.x. Epub 2010 Mar 8. Aliment Pharmacol Ther. 2010. PMID: 20222911 Free article.
Impact of an Education Programme on IBD Patients' Skills: Results of a Randomised Controlled Multicentre Study [ECIPE].
Moreau J, Hammoudi N, Marthey L, Trang-Poisson C, Nachury M, Altwegg R, Grimaud JC, Orempuller S, Hébuterne X, Aubourg A, Baudry C, Seksik P, Roblin X, Nahon S, Savoye G, Mesnard B, Stefanescu C, Simon M, Coffin B, Fumery M, Carbonnel F, Peyrin-Biroulet L, Desseaux K, Allez M; GETAID. Moreau J, et al. J Crohns Colitis. 2021 Mar 5;15(3):432-440. doi: 10.1093/ecco-jcc/jjaa195. J Crohns Colitis. 2021. PMID: 32969469 Clinical Trial.
1,093 results